Mechanisms Underlying Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia

FLT3-ITD and FLT3-TKD mutations were observed in approximately 20 and 10% of acute myeloid leukemia (AML) cases, respectively. FLT3 inhibitors such as midostaurin, gilteritinib and quizartinib show excellent response rates in patients with FLT3-mutated AML, but its duration of response may not be su...

Descripción completa

Detalles Bibliográficos
Autores principales: Eguchi, Motoki, Minami, Yosuke, Kuzume, Ayumi, Chi, SungGi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7459983/
https://www.ncbi.nlm.nih.gov/pubmed/32722298
http://dx.doi.org/10.3390/biomedicines8080245

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7459983/
https://www.ncbi.nlm.nih.gov/pubmed/32722298
http://dx.doi.org/10.3390/biomedicines8080245

Ejemplares similares